



Notes to the Editor

About AudioCure

AudioCure Pharma GmbH is a pharmaceutical R&D company headquartered in Germany and founded by Prof. Hans Rommelspacher, MD and CSO. As the former head of the Department of Clinical Neurobiology in the Psychiatric Clinic at the Charité University, Berlin, Prof. Rommelspacher has extensive experience in neuroprotection and treatments for neurodegenerative disorders. It is Prof. Rommelspacher's scientific expertise and lifelong dedication to neuroscience that led to the discovery of AC102, the company's front-runner molecule.

Hearing disorders are a global problem with no approved drug intervention available for patients suffering from any sensorineural hearing loss or tinnitus. AudioCure's mission is to turn incurable hearing loss into a treatable event. Hearing impairment affects patients in many ways, often causing difficulties acquiring spoken language and limiting job opportunities, but also leading to social withdrawal, isolation and depression¹. Hearing loss also presents a significant economic burden, reflected by an estimated loss in gross domestic product of up to 2% in developed countries.²

AudioCure's preclinical models have demonstrated the unique potential of AC102 to tackle all three crucial types of cells of the inner ear affected by hearing loss: the inner hair cells, the outer hair cells and the acoustic nerve. By protecting and restoring the cellular key players that are critical to the hearing process, the therapeutic approach of AudioCure goes beyond treating symptoms to tackle the root cause of hearing loss.

For further information, please visit www.audiocure.de.

References

¹Mortality and Burden of Diseases and Prevention of Blindness and Deafness. WHO, 2012

²Prevention of noise-induced hearing loss. WHO report, Geneva 1997

Contact

AudioCure Pharma GmbH
Frauke Luers
Phone: +49 30 221 8397 14
E-Mail: pr@audiocure.de